2020 Year in Review - Ovarian Cancer
2020 Year in Review - Ovarian Cancer | January 20, 2021
A recent study explores niraparib’s efficacy, safety, and effect on quality of life in compared age-groups.
2020 Year in Review - Ovarian Cancer | January 20, 2021
In patients with high-grade ovarian cancer harboring BRCA mutations and a confirmed response to rucaparib, BRCA homozygous deletion or rearrangement was associated with a significantly longer duration of response.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Despite substantial rates of intraoperative tumor spillages, patients with ovarian germ cell tumors (OGCTs) had an excellent prognosis, and adjuvant chemotherapy showed evidence of preventing disease recurrence.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Is subsequent chemotherapy less effective for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer who have been treated with olaparib as maintenance therapy? Here we discuss the latest findings from the SOLO2/ENGOT Ov-21 clinical trial.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Due to a variety of factors, first-line therapy with atezolizumab failed to demonstrate significant activity in patients with newly diagnosed stage III or stage IV ovarian cancer.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Olaparib maintenance monotherapy not only delays disease progression but also improves overall survival (OS) in women with platinum-sensitive relapsed ovarian cancer and a BRCA mutation.
2020 Year in Review - Ovarian Cancer | January 20, 2021
This real-world study based primarily on community-based practice data showed that a key predictor of time to next treatment and mortality in patients with advanced ovarian cancer was visible residual disease.
